About BioAtla, Inc. Common Stock
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
Market Cap
$0.02B
Employees
65
Listed Since
December 16, 2020
Industry
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Website
www.bioatla.comPhone
858-558-0708
Headquarters
11085 TORREYANA ROAD
SAN DIEGO, CA 92121
CIK
0001826892